Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
|
Pre-Market Last Trade |
Last: $ 7.81 ▼ -0.13 (-1.64%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | TEVA | NYSE | Depository Receipt |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.94 | 0.00 | 0.00 | 0.00 | 7.94 | 09:10:53 |
| Stock Trades | Traded Volume | Average Volume |
|---|---|---|
| 210 | 149,872 | 24,681,394 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:08:55 | formt | 100 | 7.81 | USD |
Teva Pharmaceutical Indu... Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | |
|---|---|---|---|---|---|
| 8.67B | 1.09B | -2.15B | -2.36 | -1.95 | 1.09B |
| Dividends Per Share | Dividend Yield | ||||
|---|---|---|---|---|---|
| 68.59M | - | 0.00% | - | - |
News Teva Pharmaceutical Indu...
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
TEVA Historical
| Period † | Open | High | Low | VWAP | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0 | 0 | 0 | 0.0000 | - | - | - |
| 1 Month | 0 | 0 | 0 | 0.0000 | - | - | - |
| 3 Months | 0 | 0 | 0 | 0.0000 | - | - | - |
| 6 Months | 0 | 0 | 0 | 0.0000 | - | - | - |
| 1 Year | 0 | 0 | 0 | 0.0000 | - | - | - |
| 3 Years | 0 | 0 | 0 | 0.0000 | - | - | - |
| 5 Years | 0 | 0 | 0 | 0.0000 | - | - | - |
| Teva Pharmaceutical Industries Ltd is the largest generic drug manufacturer in the world with more than 60 manufacturing and R&D facilities, headquartered in Israel. The company was formed in 1901 and has a portfolio of more than 3,500 medicines--roughly one out of nine generic prescriptions in the U.S. is filled with a Teva product. The company also develops branded pharmaceuticals in the central nervous system, oncology, and respiratory categories. Teva's generic drug sales represent about half of total revenue, with branded drug and distribution revenue making up the balance. Teva is an aggressive filer to bring generic drugs to market when brand patents expire and has the most generic products pending FDA approval. |
